肝细胞肝癌放疗联合免疫治疗研究进展

摘要/Abstract

郑宣, 陈波, 李晔雄. 肝细胞肝癌放疗联合免疫治疗研究进展[J]. 肝癌电子杂志, 2019, 6(4): 5-8.

参考文献 55

[1]	Torre LA, Bray F, Siegel RL , et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015,65(2):87-108.
[2]	European Association for the Study of The Liver, European Association for the Study of The Liver, European Organisation For Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma [J]. J Hepatol, 2012,56(4):908-943.
[3]	Demaria S, Bhardwaj N, Mcbride WH , et al. Combining radiotherapy and immunotherapy: a revived partnership[J]. Int J Radiat Oncol Biol Phys, 2005,63(3):655-666.
[4]	Demaria S, Ng B, Devitt ML , et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated[J]. Int J Radiat Oncol Biol Phys, 2004,58(3):862-870.
[5]	Frey B, Rubner Y, Wunderlich R , et al. Induction of Abscopal Anti-Tumor Immunity and Immunogenic Tumor Cell Death by Ionizing Irradiation - Implications for Cancer Therapies[J]. Curr Med Chem, 2012,19(12):1751-1764.
[6]	Lugade AA, Moran JP, Gerber SA , et al. Local Radiation Therapy of B16 Melanoma Tumors Increases the Generation of Tumor Antigen-Specific Effector Cells That Traffic to the Tumor[J]. 2005,174(12):7516-7523.
[7]	North RJ . Radiation-induced, immunologically mediated regression of an established tumor as an example of successful therapeutic immunomanipulation. Preferential elimination of suppressor T cells allows sustained production of effector T cells[J]. 1986,164(5):1652-1666.
[8]	Jenne CN, Kubes P . Immune surveillance by the liver[J]. Nat Immunol, 2013,14(10):996-1006.
[9]	Diehl L, Schurich A, Grochtmann R , et al. Tolerogenic maturation of liver sinusoidal endothelial cells promotes B7-homolog 1-dependent CD8+ T cell tolerance[J]. Hepatology, 2008,47(1):296-305.
[10]	Schildberg FA, Hegenbarth SI, Schumak B , et al. Liver sinusoidal endothelial cells veto CD8 T cell activation by antigen-presenting dendritic cells[J]. Eur J Immunol, 2008,38(4):957-967.
[11]	Kim HY, Park JW . Current immunotherapeutic strategies in hepatocellular carcinoma: recent advances and future directions[J]. Therap Adv Gastroenterol, 2017,10(10):805-814.
[12]	Chew V, Lai L, Pan L , et al. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses[J]. Proc Natl Acad Sci U S A, 2017,114(29):E5900-E5909.
[13]	Tada F, Abe M, Hirooka M , et al. Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma[J]. Int J Oncol, 2012,41(5):1601-1609.
[14]	Palmer DH, Midgley RS, Mirza N , et al. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma[J]. Hepatology, 2009,49(1):124-132.
[15]	El Ansary M, Mogawer S, Elhamid SA , et al. Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC[J]. J Cancer Res Clin Oncol, 2013,139(1):39-48.
[16]	Lee JH, Lee Y, Lee M , et al. A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma[J]. Br J Cancer, 2015,113(12):1666-1676.
[17]	Takayama T, Sekine T, Makuuchi M , et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial[J]. The Lancet, 2000,356(9232):802-807.
[18]	Hui D, Qiang L, Jian W , et al. A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma[J]. Dig Liver Dis, 2009,41(1):36-41.
[19]	Weng D-S, Zhou J, Zhou Q-M , et al. Minimally Invasive Treatment Combined With Cytokine-induced Killer Cells Therapy Lower the Short-term Recurrence Rates of Hepatocellular Carcinomas[J]. 2008,31(1):63-71.
[20]	Lee JH, Lee JH, Lim YS , et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma[J]. Gastroenterology, 2015,148(7):1383-1391.
[21]	Rudd CE, Taylor A, Schneider H . CD28 and CTLA-4 coreceptor expression and signal transduction[J]. Immunol Rev, 2009,229(1):12-26.
[22]	Fife BT, Bluestone JA . Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways[J]. Immunol Rev, 2008,224(1):166-182.
[23]	Sangro B, Gomez-Martin C, De La Mata M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C[J]. J Hepatol, 2013,59(1):81-88.
[24]	Duffy AG, Ulahannan SV, Makorova-Rusher O , et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma[J]. J Hepatol, 2017,66(3):545-551.
[25]	El-Khoueiry AB, Sangro B, Yau T , et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017,389(10088):2492-2502.
[26]	Wainberg ZA, Segal NH, Jaeger D , et al. Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC)[J]. J Clin Oncol, 2017,35(15_suppl):4071-4071.
[27]	Zhu AX, Finn RS, Edeline J , et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial[J]. Lancet Oncol, 2018,19(7):940-952.
[28]	Gameiro SR, Ardiani A, Kwilas A , et al. Radiation-induced survival responses promote immunogenic modulation to enhance immunotherapy in combinatorial regimens[J]. Oncoimmunology, 2014,3(e28643):1-3.
[29]	Ma Y, Kepp O, Ghiringhelli F , et al. Chemotherapy and radiotherapy: cryptic anticancer vaccines[J]. Semin Immunol, 2010,22(3):113-124.
[30]	Vanpouille-Box C, Pilones KA, Wennerberg E , et al. In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment[J]. Vaccine, 2015,33(51):7415-7422.
[31]	Golden EB, Frances D, Pellicciotta I , et al. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death[J]. Oncoimmunology, 2014,3(e28518):1-12.
[32]	崔佳宁, 王俊杰 . 免疫治疗联合放疗治疗晚期非小细胞肺癌的进展[J]. 现代肿瘤医学, 2018,26(15):2477-2480.
[33]	Thompson RF, Maity A . Radiotherapy and the tumor microenvironment: mutual influence and clinical implications[J]. Adv Exp Med Biol, 2014,772:147-165.
[34]	Dewan MZ, Galloway AE, Kawashima N , et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody[J]. Clin Cancer Res, 2009,15(17):5379-5388.
[35]	Vanpouille-Box C, Alard A, Aryankalayil MJ , et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity[J]. Nat Commun, 2017,8(15618):1-15.
[36]	Formenti SC . Optimizing Dose Per Fraction: A New Chapter in the Story of the Abscopal Effect?[J]. Int J Radiat Oncol Biol Phys, 2017,99(3):677-679.
[37]	Formenti SC, Demaria S . Combining radiotherapy and cancer immunotherapy: a paradigm shift[J]. J Natl Cancer Inst, 2013,105(4):256-265.
	[ 38 Bernstein MB, Krishnan S, Hodge JW , et al. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?[J]. Nat Rev Clin Oncol, 2016,13(8):516-524.
[39]	Gong J, Le TQ, Massarelli E , et al. Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination[J]. J Immunother Cancer, 2018,6(46):1-17.
[40]	Weichselbaum RR, Liang H, Deng L , et al. Radiotherapy and immunotherapy: a beneficial liaison?[J]. Nat Rev Clin Oncol, 2017,14(6):365-379.
[41]	Golden EB, Formenti SC . Is tumor (R)ejection by the immune system the "5th R" of radiobiology?[J]. Oncoimmunology, 2014,3(e28133):1-3.
[42]	Hiniker SM, Chen DS, Reddy S , et al. A systemic complete response of metastatic melanoma to local radiation and immunotherapy[J]. Transl Oncol, 2012,5(6):404-407.
[43]	Stamell EF, Wolchok JD, Gnjatic S , et al. The abscopal effect associated with a systemic anti-melanoma immune response[J]. Int J Radiat Oncol Biol Phys, 2013,85(2):293-295.
[44]	Postow MA, Callahan MK, Barker CA , et al. Immunologic correlates of the abscopal effect in a patient with melanoma[J]. New Engl J Med, 2012,366(10):925-931.
[45]	Silk AW, Bassetti MF, West BT , et al. Ipilimumab and radiation therapy for melanoma brain metastases[J]. Cancer Med, 2013,2(6):899-906.
[46]	Karbach J, Gnjatic S, Biskamp M , et al. Long-term complete remission following radiosurgery and immunotherapy in a melanoma patient with brain metastasis: immunologic correlates[J]. Cancer Immunol Res, 2014,2(5):404-409.
[47]	Kiess AP, Wolchok JD, Barker CA , et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment[J]. Int J Radiat Oncol Biol Phys, 2015,92(2):368-375.
[48]	Golden EB, Chachoua A, Fenton-Kerimian MB , et al. Abscopal Responses in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Treated on a Phase 2 Study of Combined Radiation Therapy and Ipilimumab: Evidence for the In Situ Vaccination Hypojournal of Radiation[J]. Int J Radiat Oncol Biol Phys, 2015,93(3):S66-S67.
[49]	Kwon ED, Drake CG, Scher HI , et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial[J]. Lancet Oncol, 2014,15(7):700-712.
[50]	Roger A, Finet A, Boru B , et al. Efficacy of combined hypo-fractionated radiotherapy and anti-PD-1 monotherapy in difficult-to-treat advanced melanoma patients[J]. Oncoimmunology, 2018,7(e1442166):1-8.
[51]	Shaverdian N, Lisberg AE, Bornazyan K , et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial[J]. Lancet Oncol, 2017,18(7):895-903.
[52]	Antonia SJ, Villegas A, Daniel D , et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer[J]. New Engl J Med, 2017,377(20):1919-1929.
[53]	Wahl DR, Stenmark MH, Tao Y , et al. Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma[J]. J Clin Oncol, 2016,34(5):452-459.
[54]	Ohri N, Dawson LA, Krishnan S , et al. Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study[J]. J Natl Cancer Inst, 2016,108(9):1-10.
[55]	Kim KJ, Kim JH, Lee SJ , et al. Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model[J]. Oncotarget, 2017,8(25):41242-41255.

肝细胞肝癌放疗联合免疫治疗研究进展

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 55

相关文章 0

编辑推荐

Metrics

本文评价